Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients.

Abstract

BACKGROUND:

The purpose of this study was to observe the incidence of falls in Parkinson's disease (PD) patients with different cognitive levels and to investigate the effect of the cholinesterase inhibitor Rivastigmine on cognitive dysfunction and falling in PD patients.

SUBJECTS AND METHODS:

Data from 176 PD patients participating in the collaborative PD study between June 2010 and June 2014 were collected; the Chinese edition of the Montreal Cognitive Assessment (MoCA) score was used to evaluate the cognitive function of patients, and falls were recorded. PD patients with cognitive dysfunction were randomly administered either a placebo or Rivastigmine. The cognitive function changes and difference in fall incidence were compared between the 2 groups.

RESULTS:

The average number of falls per person in PD patients without cognitive impairment dysfunction was significantly lower than that in patients in the PD mild cognitive impairment (PD-MCI) group and that in the PD dementia (PDD) group (p < 0.01, p < 0.001, respectively), and the incidence of falls was significantly lower than that in patients in the PD-MCI and PDD groups (p < 0.01, p < 0.01, respectively). Compared to the PD-MCI group, the incidence of falls of patients in the PDD group (OR 2.45, 95% CI 0.97-6.20, p < 0.01) and the number of falls per person were significantly increased (p < 0.01). After taking the placebo or Rivastigmine for 12 months, the MoCA scores of patients in the Rivastigmine treatment group were significantly higher than those of the control group (p = 0.002). The number of falls per person and the incidence of falls of patients in Rivastigmine treatment group were significantly lower than those in the placebo group (p < 0.01).

CONCLUSION:

This study suggests that the degree of cognitive impairment is closely associated with the incidence of falls, and the cholinesterase inhibitor Rivastigmine can delay the deterioration of cognitive function and lower the incidence of falls in PD patients.

• Authors: Zhenguang Li, Zhancai Yu, Jinbiao Zhang, Jing Wang, Chao Sun, Pengfei Wang, Jiangshan Zhang
• Journal: European neurology (Eur Neurol) Vol. 74 Issue 1-2 Pg. 86-91 ( 2015) ISSN: 1421-9913 [Electronic] Switzerland
• PMID: 26288230 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2015 S. Karger AG, Basel.

Chemical References

• Cholinesterase Inhibitors
• Rivastigmine

Topics

• Accidental Falls (prevention & control, statistics & numerical data)
• Aged
• Cholinesterase Inhibitors (therapeutic use)
• Cognitive Dysfunction (etiology)
• Female
• Humans
• Male
• Middle Aged
• Parkinson Disease (complications, drug therapy)
• Rivastigmine (therapeutic use)